Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05789589 · ClinicalTrials.gov registry record · Phase 1
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
A Phase 1 study of Cancer and Metastatic Cancer, sponsored by Baptist Health South Florida.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT05789589: Recruiting Phase 1 study of Cancer and Metastatic Cancer, sponsored by Baptist Health South Florida.
NCT05789589 is a Phase 1 study of Cancer and Metastatic Cancer that is actively recruiting participants, run by Baptist Health South Florida. The registered enrollment target is 46 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05789589, a Phase 1 study of Cancer and Metastatic Cancer, is actively recruiting participants, sponsored by Baptist Health South Florida.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and overall tumor control (how long tumor remains controlled).
Conditions Studied
Interventions
- DRUG Azeliragon
- DRUG Corticosteroid
- RADIATION Stereotactic radiosurgery
Study Locations (1)
Florida
- Miami Cancer Institute at Baptist Health, Inc. - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2023-11-17 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT05789589 shows while recruiting
NCT05789589 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which Azeliragon is the first listed.
NCT05789589 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05789589 about?
NCT05789589 is a clinical study titled "Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases". To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and overall tumor control (how long tumor remains controlled).
What is the current status of trial NCT05789589?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2023-11-17. Estimated completion is 2027-08.
What conditions does trial NCT05789589 study?
This clinical trial studies the following conditions: Cancer, Metastatic Cancer, Brain Metastases, Metastasis, Brain Metastases, Adult.
What interventions are being tested in trial NCT05789589?
The interventions under investigation include: Azeliragon (DRUG), Corticosteroid (DRUG), Stereotactic radiosurgery (RADIATION).
Who is sponsoring clinical trial NCT05789589?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05789589 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05789589's enrollment target sits among peer trials
46 444th of 615 higher than 171 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI